Prediction of human papillomavirus 16 E6 gene expression and cervical intraepithelial neoplasia progression by methylation status

International Journal of Gynecological Cancer

Volumn 19, Issue 3, 2009, Pages 321-325

  Hublarova, Pavla ^a   Hrstka, Roman ^a   Rotterova, Pavla ^b,d   Rotter, Leopold ^c,d   Coupkova, Marie ^e   Badal, Vinay ^f   Nenutil, Rudolf ^a   Vojtesek, Borivoj ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d Sanatorium Helios ^*  (United States)

^e Gynecological Ambulance   (Czech Republic)

^f INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

Cervical intraepithelial neoplasia; Cervix; E6 gene; HPV 16; Promoter methylation

Indexed keywords

MESSENGER RNA; RESTRICTION ENDONUCLEASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CELL TRANSFORMATION; CONTROLLED STUDY; DISEASE SEVERITY; DNA METHYLATION; E6 GENE; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; MAJOR CLINICAL STUDY; ONCOGENE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS GENE; VIRUS GENOME;

ADOLESCENT; ADULT; AGED; CELL TRANSFORMATION, NEOPLASTIC; CERVICAL INTRAEPITHELIAL NEOPLASIA; DISEASE PROGRESSION; DNA METHYLATION; DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 68149158305     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e31819d8a5c     Document Type: Article

References (26)

1. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006;110(5):525-541.
2. Demeret C., Desaintes C., Yaniv M., et al. Different mechanisms contribute to the E2-mediated transcriptional repression of human papillomavirus type 18 viral oncogenes. J Virol. 1997;71(12):9343-9349.
3. Tan SH, Leong LE, Walker PA, et al. The human papillomavirus type 16 E2 transcription factor binds with low cooperativity to two flanking sites and represses the E6 promoter through displacement of Sp1 and TFIID. J Virol. 1994;68(10):6411-6420.
4. Bernard HU. Gene expression of genital human papillomaviruses and considerations on potential antiviral approaches. Antivir Ther. 2002;7(4):219-237.
5. Stunkel W., Bernard HU. The chromatin structure of the long control region of human papillomavirus type 16 represses viral oncoprotein expression. J Virol. 1999;73(3):1918-1930.
6. Apt D., Chong T., Liu Y., et al. Nuclear factor I and epithelial cell-specific transcription of human papillomavirus type 16. J Virol. 1993;67(8):4455-4463.
7. Chan WK, Klock G., Bernard HU. Progesterone and glucocorticoid response elements occur in the long control regions of several human papillomaviruses involved in anogenital neoplasia. J Virol. 1989; 63(8):3261-3269.
8. Garcia-Carranca A., Thierry F., Yaniv M. Interplay of viral and cellular proteins along the long control region of human papillomavirus type 18. J Virol. 1988;62(11):4321-4330.
9. Gloss B., Bernard HU, Seedorf K., et al. The upstream regulatory region of the human papilloma virus-16 contains an E2 protein-independent enhancer which is specific for cervical carcinoma cells and regulated by glucocorticoid hormones. Embo J. 1987;6(12):3735-3743.
10. Gloss B., Chong T., Bernard HU. Numerous nuclear proteins bind the long control region of human papillomavirus type 16: a subset of 6 of 23 DNase I-protected segments coincides with the location of the cell-type-specific enhancer. J Virol. 1989;63(3):1142-1152.
11. Stacey SN, Jordan D., Williamson AJ, et al. Leaky scanning is the predominant mechanism for translation of human papillomavirus type 16 E7 oncoprotein from E6/E7 bicistronic mRNA. J Virol. 2000;74(16):7284-7297.
12. Munger K., Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res. 2002;89(2):213-228.
13. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p. 53. Science. 1990;248(4951):76-79.
14. Huibregtse JM, Scheffner M., Howley PM. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. Embo J. 1991;10(13):4129-4135.
15. Scheffner M., Huibregtse JM, Vierstra RD, et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p. 53. Cell. 1993;75(3):495-505.
16. Camus S., Menendez S., Cheok CF, et al. Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6. Oncogene. 2007;26(28):4059-4070.
17. Badal V., Chuang LS, Tan EH, et al. CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression. J Virol. 2003;77(11):6227-6234.
18. Kalantari M., Lee D., Calleja-Macias IE, et al. Effects of cellular differentiation, chromosomal integration and 5-aza-2'-deoxycytidine treatment on human papillomavirus-16 DNA methylation in cultured cell lines. Virology. 2008;374(2):292-303.
19. Kalantari M., Calleja-Macias IE, Tewari D., et al. Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J Virol. 2004;78(23):12762-12772.
20. Boon ME, Ouwerkerk-Noordam E., Suurmeijer AJH, et al. Diagnostic parameters in liquid-based cytology using a coagulant suspension fixative. Acta Cytol. 2005;49:513-519.
21. Tavassoli FA, Devilee P. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press. 2003;259-277.
22. Stoler MH. New Bethesda terminology and evidence-based management guidelines for cervical cytology findings. JAMA. 2002;287(16):2140-2141.
23. de Boer MA, Jordanova ES, Kenter GG, et al. High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients. Clin Cancer Res. 2007;13(1):132-138.
24. Wright TC Jr, Cox JT, Massad LS, et al. 2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia. Am J Obstet Gynecol. 2003;189(1):295-304.
25. Ho GY, Bierman R., Beardsley L., et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998; 338(7):423-428.
26. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev. 2004;68(2):362-372.